Valsartan ‘shows promise’ in hypertrophic cardiomyopathy
A phase 2 trial suggests early treatment may attenuate cardiac remodelling.
AusDoc brings you the latest news from the European Society of Cardiology Congress 2021.
Use of valsartan in patients with early hypertrophic cardiomyopathy (HCM) due to a pathogenic sarcomeric gene variant attenuates markers of cardiac remodelling, a trial shows.
The results of the phase 2 Valsartan for Attenuating Disease Evolution in Early-stage Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial suggest an opportunity for early treatment using the well-established drug, the authors say.
Dr Carolyn Ho from the Brigham and Women’s Hospital, Boston, US presented the trial results to delegates at the ESC Congress 2021 held on the weekend.
